Astrocytes contribute to olanzapine-mediated reversal of kleefstra syndrome-associated neurodevelopmental regression
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci195803 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Karlijn Vermeulen-Kalk und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud UMC, Nijmegen, Netherlands. Hauptthemen laut MEDLINE: Olanzapine, Astrocytes, Craniofacial Abnormalities, Intellectual Disability. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organization for Health Research and Development ZonMw, ERA-Net NEURON, China Scholarship Council.
Abstract (Originalsprache)
Kleefstra syndrome (KLEFS1) results from EHMT1 haploinsufficiency and is characterized by variable neurodevelopmental delays and psychopathology. Developmental regression, marked by the sudden loss of previously acquired daily life skills during late puberty or early adulthood, has emerged as a severe complication in individuals with KLEFS1. To investigate the clinical and molecular mechanisms underlying developmental regression and assess the therapeutic potential of olanzapine, we conducted a sequential study in an international cohort of 54 individuals with KLEFS1. Among 16 individuals treated with olanzapine, 10 exhibited a beneficial response based upon improvement of their adaptive functioning, and 4 showed temporary improvement. These clinical findings informed preclinical studies using human induced pluripotent stem cell-derived and ex-vivo cortical slices from a mouse model of KLEFS1. We identified hyperactivity in EHMT1 +/– neuronal networks cocultured with EHMT1 +/– astrocytes, a dysfunction reversible by olanzapine. Mechanistically, EHMT1 +/– astrocytes displayed elevated levels of S100B, a neuroinflammatory marker contributing to neuronal network hyperactivity. Notably, olanzapine treatment reduced S100B levels, and pharmacological inhibition or genetic knockdown of S100B in EHMT1 +/– astrocytes was sufficient to rescue the neuronal hyperactivity phenotype. These findings underscore a critical role for astrocytes in KLEFS1 pathophysiology and identify a potential cellular target for olanzapine in mitigating developmental regression. Kleefstra syndrome (KLEFS1) involves neurodevelopmental regression. Olanzapine improved symptoms in some patients, potentialy by reducing astrocyte-driven brain hyperactivity linked to elevated S100β levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Radboud UMC, Nijmegen, Netherlands.
- Centre of Excellence for Neuropsychiatry, Vincent van Gogh Institute for Psychiatry, Venray, Netherlands.
- Department for Intellectual Disabilities, Karakter Child and Adolescent Psychiatry, Ede, Netherlands.
- Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands.
- Rosamund Stone Zander Translational Neuroscience Center, Department of Neurology.
- Division of Developmental Medicine.
Förderung
- Netherlands Organization for Health Research and Development ZonMw
- ERA-Net NEURON
- China Scholarship Council
- Simons Foundation Autism Research Initiative
- NWO
Zitieren
APA
Vermeulen-Kalk, K., Wang, S., Kummeling, J., Mossink, B., Wijnant, K., Gonzales Jiménez, C., Frazier, Z., Rozumny, B., O'Donnell-Luria, A., Hanson, E., Frega, M., Linda, K., Negwer, M., Lendemeijer, B., Oudakker, A., Pop-Purceleanu, M., Janzing, J., van Dongen, L., de Vrij, F. M., …, & Kleefstra, T. (2026). Astrocytes contribute to olanzapine-mediated reversal of kleefstra syndrome-associated neurodevelopmental regression. Journal of Clinical Investigation. https://doi.org/10.1172/jci195803
Vancouver
Vermeulen-Kalk K, Wang S, Kummeling J, Mossink B, Wijnant K, Gonzales Jiménez C, et al. Astrocytes contribute to olanzapine-mediated reversal of kleefstra syndrome-associated neurodevelopmental regression. Journal of Clinical Investigation. 2026. doi:10.1172/jci195803
BibTeX
@article{VermeulenKalk2026,
author = {Vermeulen-Kalk, Karlijn and Wang, Shan and Kummeling, Joost and Mossink, Britt and Wijnant, Kim and Gonzales Jiménez, Carlos and Frazier, Zoe and Rozumny, Brian and O'Donnell-Luria, Anne and Hanson, Ellen and Frega, Monica and Linda, Katrin and Negwer, Moritz and Lendemeijer, Bas and Oudakker, Astrid and Pop-Purceleanu, Monica and Janzing, Joost and van Dongen, Linde and de Vrij, Femke Ms and Kushner, Steven A and van der Werf, Ilse and Schoenmaker, Chantal and Oomens, Wouter and Srivastava, Siddharth and Egger, Jos Im and van Bokhoven, Hans and Schubert, Dirk and Nadif Kasri, Nael and Kleefstra, Tjitske},
title = {Astrocytes contribute to olanzapine-mediated reversal of kleefstra syndrome-associated neurodevelopmental regression},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci195803}
}
EUVIMED